A nomogram based on the expression of Ki-67, steroid hormone receptors status and number of chemotherapy courses to predict pathological complete remission after preoperative chemotherapy for breast cancer

2010 ◽  
Vol 46 (12) ◽  
pp. 2216-2224 ◽  
Author(s):  
Marco Colleoni ◽  
Vincenzo Bagnardi ◽  
Nicole Rotmensz ◽  
Giuseppe Viale ◽  
Mauro Mastropasqua ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Complete Remission ◽  
Preoperative Chemotherapy ◽  
Hormone Receptors ◽  
Steroid Hormone ◽  
Steroid Hormone Receptors ◽  
Ki 67 ◽  
Pathological Complete Remission

Preoperative concurrent chemo- and endocrine therapies for women with large operable breast cancer expressing steroid hormone receptors

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 21153-21153
Author(s):  
S. Dellapasqua ◽  
A. Balduzzi ◽  
R. Torrisi ◽  
R. Ghisini ◽  
G. Peruzzotti ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Endocrine Therapy ◽  
Preoperative Chemotherapy ◽  
Hormone Receptors ◽  
Objective Response ◽  
Breast Conserving Surgery ◽  
Steroid Hormone Receptors ◽  
Ki 67 ◽  
Pathological Complete Remission ◽  
Chemotherapy Study

21153 Background: Preoperative chemotherapy and endocrine therapy yielded low pathological complete remission (pCR) rates in patients with endocrine responsive breast cancer. Methods: Patients with large operable endocrine responsive (ER ≥ 10% of the cells) breast cancer (cT2-T3, N0–2, M0) were treated in 2 consecutive studies with preoperative chemotherapy (Study I: 6 courses of either fluorouracil, leucovorin, vinorelbine (FLN), or vinorelbine, cisplatin, and continuous infusion of fluorouracil (ViFuP), chosen at the discretion of the treating physician; Study II: an oral regimen with capecitabine and vinorelbine (CAVINO). In both studies concurrent endocrine therapies (letrozole, either alone or if premenopause, with triptorelin) were given. Results: Sixty-five (58 evaluable) and fifty-five (all evaluable) patients were enrolled to Studies I and II, (ER >50%, 51 and 50; Ki 67 = 20%, 42 and 39; cT2/3: 36 / 22 and 35 / 20; premenopausal 40 and 38) respectively. In Study I there were 43 objective responders (74%, 95% CI 63–85%), 4 of whom had pCR. In Study II 34 patients (62%, 95% CI 49–75%) had an objective response. Breast conserving surgery became possible for 64% and 62% of the patients in Study I and II, respectively. Conclusions: Intravenous, non anthracycline containing regimens together with tailored menopause status-adapted endocrine therapy, warrants further investigations in the preoperative setting. No significant financial relationships to disclose.

scholarly journals Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy

2008 ◽  
Vol 116 (2) ◽  
pp. 359-369 ◽  
Author(s):  
Marco Colleoni ◽  
Vincenzo Bagnardi ◽  
Nicole Rotmensz ◽  
Richard D. Gelber ◽  
Giuseppe Viale ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Preoperative Chemotherapy ◽  
Hormone Receptors ◽  
Steroid Hormone ◽  
Steroid Hormone Receptors ◽  
Breast Cancer Subtypes ◽  
Cancer Subtypes
Sign in / Sign up

Export Citation Format

Share Document